Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia-Reference-Cited by-同舟云学术

Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia

Published:2019-11-02 Issue:6 Volume:19 Page:717-723
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Janzic Urska¹^ORCID,Knez Lea²³,Janzic Andrej⁴,Cufer Tanja¹⁵

Affiliation:

1. Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia

2. Pharmacy Department, University Clinic Golnik, Golnik, Slovenia

3. Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia

4. Division of Pharmacoeconomics, Market Monitoring and HTA, Agency for Medicinal Products and Medical Devices of the Republic of Slovenia, Ljubljana, Slovenia

5. Medical Faculty, University of Ljubljana, Ljubljana, Slovenia

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2019.1702879

Reference26 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review

3. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

4. The cost and burden of cancer in the European Union 1995–2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease;Journal of Clinical Medicine;2024-07-22

2. Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit;ESMO Open;2023-08

3. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?;Expert Review of Pharmacoeconomics & Outcomes Research;2023-07-26

4. HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review;Journal of Health Economics and Outcomes Research;2023-06-20

5. HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review;Journal of Health Economics and Outcomes Research;2023-06-20